Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We believe this to be the first case reported of extraosseous myelomatosis seen clincally with lower urinary tract symptoms. Extraskeletal spread of myelomatosis which reportedly occurs in two thirds of cases is discovered postmortem. Immunoglobulin A prevails in this type of myelomatosis. Clinical course and autopsy findings are discussed.
Urology 1976 Sep
PMID:Extraosseous myelomatosis. Clinical presentation with symptoms in lower urinary tract. 96 82

We studied the effects of dinitrato (1,2,-diaminocyclohexane)platinum (NSC 239851) on murine myeloma Adj. PC-5 and hemopoietic precursor cells. The median survival time of tumor-bearing mice was significantly affected by i.p. injections of this agent. While 14 mg/kg was a toxic dose, as little as 2 mg/kg prolonged the survival for over 100 days. When cells from normal marrow and actively regenerating marrows were exposed to the agent in culture tubes, washed, and assayed for the surviving hemopoietic precursors, similar sensitivity curves were observed. This result indicates the absence of cell cycle dependency of the agent. When marrow cells were exposed to NSC 239851 at 4 degrees in culture, almost total abrogation of the cytotoxicity was noted. This observation, unlike that from the experiment with the inorganic platinum congener, cis-diamminedichloroplatinum, suggests that the transport of this agents is an active process.
Cancer Res 1976 Sep
PMID:Effects of Dintrato(1,2-diaminocyclohexane)platinum (NSC 239851) On murine myeloma and hemopoietic precursor cells. 97 83

Recurrent gangrenous leg ulcers were associated with a monoclonal IgGk cryoglobulinaemia, though without overt myeloma. Cryoprecipitation of the serum in vitro gave a reversible gel with microtubular structure, built from the monomer and with a high degree of order. The same structure was found distending the superficial vessels of the ulcer biopsy, as well as extravascularly. There was no vasculitis, and luminal obstruction appeared responsible for the ulceration. Microtubular structures occur in nature among diverse proteins and viruses. The protein studied here is similar to a reported instance of myeloma cryo-IgGk.
J Pathol 1976 Sep
PMID:Cryoimmunoglobulin IgGk with microtubular ultrastructure associated with pyoderma gangrenosum. 97 11

Lactic dehydrogenase (LDH), glutamic-oxalacetic transaminase (GOT), and acid and alkaline phosphatase activities in bone marrow and in cubital vein serum were compared. For patients without cancer, marrow serum LDH attained levels four times as high, and GOT and alkaline phosphatase, levels twice as high as those normal for cubital vein serum; levels of acid phosphatase were the same for both sources. For patients with cancer, significant increase of enzyme levels over reference levels depends on the tumor origin and on the presence and localization of metastases. Marrow enzyme levels may become elevated with or without concurrent elevation in cubital vein serum. Concurrent elevations were found with colonic carcinoma and lymphoid leukemia, and noncurrent elevations, with prostatic cancer, myeloid leukemia, and myeloma. A nonconcurrent elevation of marrow enzymes indicates that the origin of the enzyme is in the marrow, whereas with concurrent elevation, the source of the enzyme may be another organ.
Cancer 1976 Sep
PMID:Enzymes in peripheral and bone marrow serum in patients with cancer. 98 36

A case report of a patient with amyloidosis presented in which macroglossia and bilateral carpal tunnel syndrome were the initial features and myeloma was the probable underlying cause.
J Oral Surg 1975 Sep
PMID:Amyloidosis, macroglossia, and carpal tunnel syndrome associated with myeloma. 105 92

Two cases of the development of acute myeloid leukemia (AML) after treatment with alkylating agents are reported. In Case 1, melphalan and then cyclophosphamide had been given for multiple myeloma. 46 months after onset of cytostatic treatment AML occurred, as confirmed cytochemically and by qualitative determination of urinary lysozyme. In Case 2, cyclophosphamide had been given for rheumatoid arthritis. After a latency of 34 months 'smouldering leukaemia' developed with an atypical monocytic leukaemic cell population. In a third case, multiple myeloma and monocytic leukaemia developed synchronously. The causative role of melphalan and cyclophosphamide in the development of AML seems securely established. Despite the risk of alkylating agents in the treatment of multiple myeloma or Hodgkin's disease causing AML, they should not be replaced, as other drugs have been shown to be less beneficial. On the other hand, alkylating agents should be used with great caution in the treatment of non-malignant diseases.
Dtsch Med Wochenschr 1975 Sep 26
PMID:[Plasmocytoma, alkylating agents, and acute myeloid leukemia (author's transl)]. 105 6

The specific antiserum against a type of ferritin that is especially common to leukemia cells and the placenta was used to test, by countercurrent immunoelectrophoresis, sera from humans with various diseases. The best results were obtained with leukemia; patients with chronic myelogenous leukemia in blastic phase, acute myelogenous leukemia, lymphogenous leukemia, and unclassifiable juvenile leukemia frequently showed a positive reaction, but patients with chronic myelogenous leukemia in static phase did not. The average incidence of positive reaction among all leukemia patients was 54.0%. Patients with other malignant tumors (i.e., multiple myeloma, malignant lymphoma and carcinomas of the stomach, rectum, and liver) also often showed a positive reaction. The average incidence of positive reaction among all the patients with malignant diseases of the hematopoietic system, except for leukemia, was 34.3%, and that among patients with nonhematologic malignant neoplasms was 36.8%. However, the incidence of a positive reaction in patients with benign diseases and healthy individuals was less than 3%.
J Natl Cancer Inst 1975 Sep
PMID:Antiserum against leukemia cell ferritin as a diagnostic tool for malignant neoplasms. 105 55

Translation of total polysomal RNA from sarcoma 180 ascites cells in a wheat germ cell-free system produces two major polypeptides, A and B, with molecular weights of 50,000 and 45,000, respectively. Fractionation on Millipore filters or on oligo(dT)-cellulose leads to retention of the mRNA specific for protein A in the poly(A)-containing fraction and to accumulation of the B mRNA in the unadsorbed poly(A)-deficient fraction. The mRNA for B sediments at approximately 18 S; it is released as a 50S ribonucleorprotein upon EDTA treatment of polysomes. Its translation is particularly sensitive to an inhibitor present in the polysomal RNA. The poly(A)-deficient mRNA for the 45,000 dalton polypeptide is also present in mouse myeloma MPC-11 cells, where it seems to be localized in membrane-bound polysomes.
Proc Natl Acad Sci U S A 1976 Sep
PMID:A major species of mammalian messenger RNA lacking a polyadenylate segment. 106 3

Myeloma-associated and casein-induced murine amyloidosis were used as models to study the role of lymphocytes and macrophages in amyloid formation. Amyloidosis occurred rarely and in small amounts in Balb/C mice with immunoglobulin (Ig)-producing myeloma tumours but large amounts could be induced by injections of casein. Fluorescent staining of both forms of amyloid deposits by means of anti-casein- and anti-myeloma-amyloid antibodies indicated that they either crossreacted or coexisted. Nor abnormality of Ig biosynthesis was detected in amyloidosis, suggesting that abnormal degradation was responsible for production of the Ig form of amyloid. Although spleen lymphocytes of casein-injected mice with amyloidosis demonstrated diminished cellular immunologic responses, this did not indicate generalized immunologic incompetence. The non-Ig form of amyloid in casein-injected mice was shown to be produced by macrophages, and a technique was developed for increasing the yield of amyloid-containing cells.
Can Med Assoc J 1975 Sep 20
PMID:Experimental murine amyloidosis: a model system for studying amyloid formation. 108 Apr 30

We studied a subpopulation of the thymus-dependent rosette-forming lymphocytes from the peripheral blood of normal individuals and of untreated patients with solid tumors or hematological cancers. This subpopulation of the thymus-dependent rosette-forming cells (T-RFC), termed the "active T-RFC," may be relatively more immunocompetent than the total thymus-dependent population. The mean percentages and absolute numbers of active T-RFC of 40 healthy adult controls were 25.8 +/- 4.3 and 626 +/- 213, respectively. There was no difference in the percentage of active T-RFC between the controls (smokers and nonsmokers) and the 102 untreated patients with solid (localized or metastasized) tumors, 4 patients with Hodgkin's disease, or the 10 patients with non-Hodgkin's lymphomas. However, the absolute number of active T-RFC was significantly less in the cancer patients than in the controls. Eight patients with chronic lymphocytic leukemia had lower percentages but higher absolute numbers of active T-RFC, whereas 6 patients with multiple myeloma had higher percentage and lower absolute numbers than the controls. Following radiation therapy, 61 patients with solid tumors showed no difference in the percentage of active T-RFC, but the corresponding absolute numbers declined significantly. A good correlation was seen with patients having positive microbial skin test responses and normal percentage of active T-RFC. The significance of both the percentages and absolute numbers of active T-RFC and their relationship to patient status are discussed.
Cancer Res 1976 Sep
PMID:Active T-rosette-forming cells in the peripheral blood of cancer patients. 108 31


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>